Merck-partnered antibody maker readies $300M IPO as HKEX picks up pace
Three weeks after InnoCare launched its IPO into the welcoming embrace of HKEX investors, Akesobio is looking to one-up the company with its own $300 million (HKD$2.34 billion) raise.
Partnered with Merck, Akesobio’s pitch centers around a suite of in-house technologies that it says generate superior antibodies against known targets such as PD-1, CTLA-4, IL-12 and IL-23. Having kicked off pre-marketing on Monday, it expects to make a public debut this month.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.